Source:http://linkedlifedata.com/resource/pubmed/id/11375053
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2001-5-25
|
| pubmed:abstractText |
HIV-1 can persist in infected patients despite undetectable plasma viremia. To characterize the residual viral load, repetitive blood and tonsillar samples were collected from 11 HIV-1-positive individuals before and during 96 weeks of therapy with zidovudine, lamivudine, and indinavir. HIV-1 RNA in tonsils was quantified by RT-PCR and infectious HIV-1 provirus by the limiting dilution assay. Genotypic resistance analyses and biological characterization were performed on plasma virus, blood, and tonsillar isolates. Tonsillar infectious HIV-1 provirus and HIV-1 RNA declined by 2 and 3 log(10), respectively, but 10(3)-10(4) cells, less than 0.5% of the total body CD4(+) T cell population carrying infectious HIV-1 provirus, remained involved in active viral replication of drug-sensitive R5 viruses. Thus, the dominant HIV-1 residual infection consists of < or = 10(6) latently infected CD4(+) cells. Plasma HIV-1 RNA decline of > 1.5 log(10) during the first 2 weeks of therapy may indicate low levels of this latent reservoir. Whereas the reservoir of latently infected cells remains stable, actively replicating HIV-1 continuously declines during prolonged antiretroviral therapy. Thus, although viral eradication seems unlikely, antiretroviral therapy may induce an extended period of virologic latency in HIV-1-positive individuals.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Indinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0889-2229
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
577-86
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11375053-Anti-HIV Agents,
pubmed-meshheading:11375053-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:11375053-CD4 Lymphocyte Count,
pubmed-meshheading:11375053-Disease Progression,
pubmed-meshheading:11375053-HIV Infections,
pubmed-meshheading:11375053-HIV Protease Inhibitors,
pubmed-meshheading:11375053-HIV-1,
pubmed-meshheading:11375053-Humans,
pubmed-meshheading:11375053-Indinavir,
pubmed-meshheading:11375053-Lamivudine,
pubmed-meshheading:11375053-Longitudinal Studies,
pubmed-meshheading:11375053-Lymphoid Tissue,
pubmed-meshheading:11375053-Phenotype,
pubmed-meshheading:11375053-Proviruses,
pubmed-meshheading:11375053-RNA, Viral,
pubmed-meshheading:11375053-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:11375053-Viral Load,
pubmed-meshheading:11375053-Viremia,
pubmed-meshheading:11375053-Virus Replication,
pubmed-meshheading:11375053-Zidovudine
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
|
| pubmed:affiliation |
Department of Microbiology and Immunology, Gade Institute, Center for Research in Virology, University of Bergen, N-5020 Bergen, Norway. annema.riise@vir.uib.no
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|